China patent notification boosts PolTREG’s development of Treg cell therapy in multiple sclerosis

  • China’s National Intellectual Property Administration has issued notification to grant patent to PolTREG
  • Chinese patent covers intrathecal administration of PolTREG’s PTG-007 Treg cell therapy to treat multiple sclerosis
  • Intrathecal administration demonstrated promising result in Phase I clinical trial
  • PolTREG set to launch one Phase 2 study in each of two types of MS: relapsing-remitting (RRMS) and primary progressive (PPMS) in Q4 2024

Gdańsk, Poland – 16 September 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, today announces that China’s National Intellectual Property Administration, PRC (CNIPA) has issued a notification to grant a patent for the intrathecal administration of the company’s cellular therapies in patients with multiple sclerosis (MS). The intrathecal administration is an established method used to deliver a therapy across the blood-brain barrier via injection into the subarachnoid space.

“We are about to launch two new clinical studies with PTG-007 in patients with multiple sclerosis, so it is welcome news that China has issued us a patent for the intrathecal  administration of the therapy. This method has shown superior results to systemic administration in our earlier work in neurodegenerative diseases, as it bypasses the blood-brain barrier. Having just presented our unrivalled long-term data in type 1 diabetes patients treated with systemically administered PTG-007, we will continue to highlight the potential of Treg cell therapies in a widening range of autoimmune diseases, including neurodegenerative diseases like MS and Amyotrophic Lateral Sclerosis,” said Prof Piotr Trzonkowski, CEO of PolTREG.

In an exploratory Phase 1/2a safety study of PTG-007 in RRMS, patients who had received intrathecal administration showed no increase in existing lesions in the brain, and almost no new lesions, a far superior result compared to patients who had received PTG-007 intravenously, and a surprisingly positive signal for such a small study in 14 individuals, only 3 of whom received intrathecal administration. Two large studies to be launched in Poland later this year will aim to confirm these encouraging results. The studies will have a combined 105 patients: 60 for PPMS and 45 for RRMS. Each trial will have three arms, with primary endpoints a reduced deterioration in new and existing lesions, and the number of serious adverse events.

PolTREG is advancing one of the largest and most advanced pipelines for Treg therapies for autoimmune disease, developing both polyclonal and engineered cells.  Its lead candidate, PTG-007, an autologous polyclonal Treg treatment, is in mid-stage clinical studies for type 1 diabetes (T1D). Earlier this September, PolTREG presented results from a long-term monitoring study showing that a proportion of early-onset T1D patients having received PTG-007 remained in clinical remission up to 12 years later, and several patients were insulin-independent for up to two years after PTG-007 treatment. PolTREG is preparing to launch a Phase 2 study in presymptomatic T1D patients during the fourth quarter and, next year, PolTREG expects to start a first-in-human trial of its engineered CAR-Treg, using the proven PTG-007 platform, for treatment of MS and amyotrophic lateral sclerosis. The company also is in preclinical development with two additional types of engineered Treg cell therapies, Antigen-specific Tregs and T-cell receptor (TCR) Tregs.

To read more about the clinical trials PolTREG has completed, please click on: https://poltreg.com/tregs-therapy/#publications

PolTREG manufactures all its Treg therapeutics at its own GMP-certified manufacturing facility. It is the first company in the world to have administered Treg therapies to patients, and, under a hospital exemption valid in Poland, the first company to start receiving revenues from a Treg therapeutic for autoimmune disease. Its GMP manufacturing facility is one of Europe’s largest and most advanced, boasting over 2,100 sqm of laboratory space, including 15 production lines.

PolTREG has the option to substantially expand the facility to accommodate manufacturing of next-generation engineered therapies and cell therapies. It can ship its wide range of cellular therapy products across Europe within 24 hours.

About PolTREG
PolTREG is a global leader in developing autoimmune therapies based on T-regulatory cells (Tregs).  Its lead product, PTG-007, autologous Treg treatment for early-onset Type-1 Diabetes (T1D) is ready for Phase 2/3 clinical testing, for which the company is seeking a partnership. The company will launch Phase 2 trials for PTG-007 to treat Multiple Sclerosis (MS) in the second half of 2024, for RRMS and PPMS. PolTREG also has engineered Tregs, including CAR-Tregs, antigen-specific Tregs and TCR-Tregs, in the preclinical stage. PolTREG has completed four clinical trials with more than 100 patients treated with Tregs.

For more information please visit www.poltreg.com.

For further information please contact:

PolTREG S.A.
Prof Piotr Trzonkowski
Chief Executive Officer
ir@poltreg.com
+48 512 532 401

Investor Relations
Frank Hoerning-Andersen
Cohesion Bureau
+45 25 66 86 02
frank.hoerning@cohesionbureau.com

Media Relations

Douwe Miedema
Cohesion Bureau
+352 621 562 764
douwe.miedema@cohesionbureau.com

Important information
The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes”, “estimates,” “anticipates”, “expects”, “intends”, “may”, “will”, “plans”, “continue”, “ongoing”, “potential”, “predict”, “project”, “target”, “seek” or “should”, and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The company’s actual results may differ materially from those predicted by the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

Attachment

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.